Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
11421 | 983 | 38.4 | 82% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
317 | 3 | HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA | 39408 |
1452 | 2 | CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB | 7818 |
11421 | 1 | ANILINOQUINAZOLINE//4 ANILINOQUINAZOLINE//VEGFR 2 INHIBITOR | 983 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ANILINOQUINAZOLINE | authKW | 448840 | 2% | 85% | 17 |
2 | 4 ANILINOQUINAZOLINE | authKW | 386654 | 2% | 66% | 19 |
3 | VEGFR 2 INHIBITOR | authKW | 308786 | 1% | 76% | 13 |
4 | COMBI MOLECULE | authKW | 289111 | 1% | 85% | 11 |
5 | CANC DRUG | address | 279551 | 1% | 75% | 12 |
6 | QUINAZOLINE | authKW | 226348 | 7% | 11% | 69 |
7 | MED ONCOL MEDCANC DRUG | address | 217433 | 1% | 100% | 7 |
8 | EGFR TK INHIBITORS | authKW | 180719 | 1% | 73% | 8 |
9 | KDR KINASE | authKW | 180719 | 1% | 73% | 8 |
10 | CANC DRUG MED MED ONCOL | address | 155310 | 1% | 100% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Chemistry, Medicinal | 32412 | 53% | 0% | 525 |
2 | Chemistry, Organic | 4194 | 30% | 0% | 296 |
3 | Pharmacology & Pharmacy | 631 | 17% | 0% | 166 |
4 | Biochemistry & Molecular Biology | 501 | 22% | 0% | 219 |
5 | Oncology | 208 | 10% | 0% | 94 |
6 | Chemistry, Multidisciplinary | 178 | 12% | 0% | 114 |
7 | Computer Science, Interdisciplinary Applications | 141 | 4% | 0% | 38 |
8 | Crystallography | 84 | 3% | 0% | 31 |
9 | Mathematical & Computational Biology | 67 | 2% | 0% | 18 |
10 | Biochemical Research Methods | 34 | 3% | 0% | 29 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CANC DRUG | 279551 | 1% | 75% | 12 |
2 | MED ONCOL MEDCANC DRUG | 217433 | 1% | 100% | 7 |
3 | CANC DRUG MED MED ONCOL | 155310 | 1% | 100% | 5 |
4 | MED ONCOLCANC DRUG | 155310 | 1% | 100% | 5 |
5 | MED MED ONCOLCANC DRUG | 99397 | 0% | 80% | 4 |
6 | BIOMMUNOTHER Y | 62124 | 0% | 100% | 2 |
7 | CANC DRUG HLTH | 62124 | 0% | 100% | 2 |
8 | CHEM SCI ONCOL IMMUNOINFLAMMATORY | 62124 | 0% | 100% | 2 |
9 | MED ONCOLHLTH ROYAL VICTORIA HOSP | 62124 | 0% | 100% | 2 |
10 | RD FINE CHEM GUIZHOU PROV | 62124 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 23491 | 14% | 1% | 138 |
2 | JOURNAL OF MEDICINAL CHEMISTRY | 11672 | 9% | 0% | 90 |
3 | BIOORGANIC & MEDICINAL CHEMISTRY | 9438 | 6% | 0% | 63 |
4 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 8291 | 5% | 1% | 50 |
5 | CHEMICAL BIOLOGY & DRUG DESIGN | 6763 | 2% | 1% | 19 |
6 | JOURNAL OF MOLECULAR GRAPHICS & MODELLING | 3238 | 1% | 1% | 14 |
7 | CURRENT MEDICINAL CHEMISTRY | 2792 | 2% | 0% | 20 |
8 | EXPERT OPINION ON THERAPEUTIC PATENTS | 2713 | 1% | 1% | 14 |
9 | MEDICINAL CHEMISTRY | 2251 | 1% | 1% | 8 |
10 | ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 1853 | 1% | 1% | 8 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ANILINOQUINAZOLINE | 448840 | 2% | 85% | 17 | Search ANILINOQUINAZOLINE | Search ANILINOQUINAZOLINE |
2 | 4 ANILINOQUINAZOLINE | 386654 | 2% | 66% | 19 | Search 4+ANILINOQUINAZOLINE | Search 4+ANILINOQUINAZOLINE |
3 | VEGFR 2 INHIBITOR | 308786 | 1% | 76% | 13 | Search VEGFR+2+INHIBITOR | Search VEGFR+2+INHIBITOR |
4 | COMBI MOLECULE | 289111 | 1% | 85% | 11 | Search COMBI+MOLECULE | Search COMBI+MOLECULE |
5 | QUINAZOLINE | 226348 | 7% | 11% | 69 | Search QUINAZOLINE | Search QUINAZOLINE |
6 | EGFR TK INHIBITORS | 180719 | 1% | 73% | 8 | Search EGFR+TK+INHIBITORS | Search EGFR+TK+INHIBITORS |
7 | KDR KINASE | 180719 | 1% | 73% | 8 | Search KDR+KINASE | Search KDR+KINASE |
8 | VEGFR2 | 145069 | 6% | 8% | 56 | Search VEGFR2 | Search VEGFR2 |
9 | EGFR INHIBITORS | 95902 | 3% | 11% | 27 | Search EGFR+INHIBITORS | Search EGFR+INHIBITORS |
10 | 1 4 DIHYDROINDENO1 2 CPYRAZOLES | 93186 | 0% | 100% | 3 | Search 1+4+DIHYDROINDENO1+2+CPYRAZOLES | Search 1+4+DIHYDROINDENO1+2+CPYRAZOLES |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | ZHANG, J , SHAN, Y , PAN, X , HE, L , (2011) RECENT ADVANCES IN ANTIANGIOGENIC AGENTS WITH VEGFR AS TARGET.MINI-REVIEWS IN MEDICINAL CHEMISTRY. VOL. 11. ISSUE 11. P. 920-946 | 70 | 63% | 10 |
2 | LIPUNOVA, GN , NOSOVA, EV , CHARUSHIN, VN , CHUPAKHIN, ON , (2016) SYNTHESIS AND ANTITUMOUR ACTIVITY OF 4-AMINOQUINAZOLINE DERIVATIVES.RUSSIAN CHEMICAL REVIEWS. VOL. 85. ISSUE 7. P. 759 -793 | 85 | 46% | 0 |
3 | KONG, Y , QU, D , CHEN, XY , GONG, YN , YAN, AX , (2016) SELF-ORGANIZING MAP (SOM) AND SUPPORT VECTOR MACHINE (SVM) MODELS FOR THE PREDICTION OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR/ERBB-1) INHIBITORS.COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING. VOL. 19. ISSUE 5. P. 400 -411 | 63 | 57% | 1 |
4 | WANG, C , GAO, H , DONG, J , WANG, F , LI, P , ZHANG, J , (2014) INSIGHT INTO THE MEDICINAL CHEMISTRY OF EGFR AND HER-2 INHIBITORS.CURRENT MEDICINAL CHEMISTRY. VOL. 21. ISSUE 11. P. 1336-1350 | 60 | 55% | 4 |
5 | LIU, F , TANG, BD , LIU, H , LI, L , LIU, GN , CHENG, Y , XU, Y , CHEN, WW , HUANG, YJ , (2016) 4-ANILINOQUINAZOLINE DERIVATIVES WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR ACTIVITY.ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. VOL. 16. ISSUE 12. P. 1652 -1664 | 35 | 66% | 0 |
6 | LA MOTTA, C , SARTINI, S , TUCCINARDI, T , NERINI, E , DA SETTIMO, F , MARTINELLI, A , (2009) COMPUTATIONAL STUDIES OF EPIDERMAL GROWTH FACTOR RECEPTOR: DOCKING RELIABILITY, THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS, AND VIRTUAL SCREENING STUDIES.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 52. ISSUE 4. P. 964-975 | 40 | 56% | 23 |
7 | SRIVASTAVA, SK , KUMAR, V , AGARWAL, SK , MUKHERJEE, R , BURMAN, AC , (2009) SYNTHESIS OF QUINAZOLINES AS TYROSINE KINASE INHIBITORS.ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. VOL. 9. ISSUE 3. P. 246-275 | 29 | 76% | 11 |
8 | SCHENONE, S , BONDAVALLI, F , BOTTA, M , (2007) ANTIANGIOGENIC AGENTS: AN UPDATE ON SMALL MOLECULE VEGFR INHIBITORS.CURRENT MEDICINAL CHEMISTRY. VOL. 14. ISSUE 23. P. 2495 -2516 | 53 | 37% | 56 |
9 | LI, DD , HOU, YP , WANG, W , ZHU, HL , (2012) EXPLORATION OF CHEMICAL SPACE BASED ON 4-ANILINOQUINAZOLINE.CURRENT MEDICINAL CHEMISTRY. VOL. 19. ISSUE 6. P. 871-892 | 42 | 42% | 7 |
10 | MOWAFY, S , FARAG, NA , ABOUZID, KAM , (2013) DESIGN, SYNTHESIS AND IN VITRO ANTI-PROLIFERATIVE ACTIVITY OF 4,6-QUINAZOLINEDIAMINES AS POTENT EGFR-TK INHIBITORS.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. VOL. 61. ISSUE . P. 132 -145 | 24 | 67% | 20 |
Classes with closest relation at Level 1 |
Rank | Class id | link |
---|---|---|
1 | 35107 | DIARYLAMIDE//DIARYLUREA//A375P |
2 | 24850 | TYRPHOSTIN//AG957//INOSTAMYCIN |
3 | 4440 | NIMOTUZUMAB//CETUXIMAB//EGFR |
4 | 18265 | VANDETANIB//NINTEDANIB//CEDIRANIB |
5 | 3264 | QUINAZOLINONE//43H QUINAZOLINONES//2 3 DIHYDROQUINAZOLIN 41H ONES |
6 | 1475 | VEGF//FLT 1//VEGF RECEPTORS |
7 | 10711 | SRC//SRC INHIBITORS//SARACATINIB |
8 | 23991 | REGORAFENIB//N DESETHYL SUNITINIB//N DESMETHYL IMATINIB |
9 | 11391 | GEWALD REACTION//THIENO2 3 DPYRIMIDINE//THIENOPYRIMIDINE |
10 | 147 | GEFITINIB//EGFR MUTATION//ERLOTINIB |